Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)

E-ISSN： 1873-4286|19|15|2737-2746

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.15, 2013-03, pp. : 2737-2746

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Treatment Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)

Current Drug Discovery Technologies, Vol. 4, Iss. 2, 2007-08 ,pp. : 133-140

Bentham Science Publishers

Access to resources Recommend Favorite

Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 8, Iss. 4, 2008-12 ,pp. : 301-307

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease

Mini Reviews in Medicinal Chemistry, Vol. 15, Iss. 14, 2015-12 ,pp. : 1187-1194

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for non-alcoholic fatty liver disease

By Federico Alessandro Niosi Marco Vecchio Blanco Camillo Del Loguercio Carmela

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 145-158

Informa Healthcare

Access to resources Recommend Favorite

Non-alcoholic fatty liver disease: a massive problem

By Day Christopher P

Clinical Medicine, Vol. 11, Iss. 2, 2011-04 ,pp. : 176-178

Royal College Of Physicians

Access to resources Recommend Favorite